JNJ

166.87

-0.51%↓

NVS

116.6

-0.32%↓

ABT

128.27

+0.49%↑

TMO

474.8

-1.64%↓

ISRG

498.66

+0.44%↑

JNJ

166.87

-0.51%↓

NVS

116.6

-0.32%↓

ABT

128.27

+0.49%↑

TMO

474.8

-1.64%↓

ISRG

498.66

+0.44%↑

JNJ

166.87

-0.51%↓

NVS

116.6

-0.32%↓

ABT

128.27

+0.49%↑

TMO

474.8

-1.64%↓

ISRG

498.66

+0.44%↑

JNJ

166.87

-0.51%↓

NVS

116.6

-0.32%↓

ABT

128.27

+0.49%↑

TMO

474.8

-1.64%↓

ISRG

498.66

+0.44%↑

JNJ

166.87

-0.51%↓

NVS

116.6

-0.32%↓

ABT

128.27

+0.49%↑

TMO

474.8

-1.64%↓

ISRG

498.66

+0.44%↑

Search

Ionis Pharmaceuticals Inc

Abierto

SectorSalud

43.31 4.49

Resumen

Variación precio

24h

Actual

Mínimo

41.4

Máximo

45.5

Métricas clave

By Trading Economics

Ingresos

-43M

-147M

Ventas

-95M

132M

Margen de beneficio

-111.645

Empleados

1,069

EBITDA

-63M

-144M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+39.46% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2B

6.6B

Apertura anterior

38.82

Cierre anterior

43.31

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

59 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2024, 17:01 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sept 2024, 11:00 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

39.46% repunte

Estimación a 12 meses

Media 57.85 USD  39.46%

Máximo 78 USD

Mínimo 38 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

11

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

59 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.